Metropolis Healthcare Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

It's been a good week for Metropolis Healthcare Limited (NSE:METROPOLIS) shareholders, because the company has just released its latest second-quarter results, and the shares gained 3.1% to ₹571. Metropolis Healthcare reported ₹5.0b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of ₹3.60 beat expectations, being 9.0% higher than what the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the latest results, Metropolis Healthcare's 19 analysts are now forecasting revenues of ₹19.1b in 2027. This would be an okay 7.0% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to expand 15% to ₹12.38. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹19.1b and earnings per share (EPS) of ₹12.38 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

Check out our latest analysis for Metropolis Healthcare

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹666. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Metropolis Healthcare analyst has a price target of ₹760 per share, while the most pessimistic values it at ₹550. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Metropolis Healthcare's past performance and to peers in the same industry. It's clear from the latest estimates that Metropolis Healthcare's rate of growth is expected to accelerate meaningfully, with the forecast 14% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 8.2% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 18% per year. It seems obvious that, while the future growth outlook is brighter than the recent past, Metropolis Healthcare is expected to grow slower than the wider industry.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at ₹666, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Metropolis Healthcare going out to 2029, and you can see them free on our platform here..

Before you take the next step you should know about the 1 warning sign for Metropolis Healthcare that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.